Clinical Trial Update: Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction [NA]

View source ↗

Summary

Boston Scientific's EMBLEM S-ICD was studied for primary prevention in patients with low ejection fraction, and the trial results were posted in January 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Ventricular Fibrillation
• Ventricular Tachycardia

Drugs mentioned

• EMBLEM S-ICD

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Ventricular Fibrillation, Ventricular Tachycardia | NA | Status: COMPLETED | Results posted: 2021-01-08